Back to mobile site

SAGE Therapeutics (SAGE) Says Brexanolone Achieved Primary Endpoints in Both Phase 3 Trials in Postpartum Depression

November 9, 2017 6:28 AM EST Send to a Friend
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login